Cogent Biosciences, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. Cogent is a clinical-stage biotechnology company developing precision therapies; it had no approved products and generated no product-sales revenue.
Financial highlights
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue from product sales | None | None | None | None |
| Research and development expense | $29.9 million | $14.8 million | $84.9 million | $35.4 million |
| General and administrative expense | $6.9 million | $5.0 million | $19.2 million | $14.5 million |
| Total operating expenses | $36.8 million | $19.8 million | $104.1 million | $49.9 million |
| Net loss | $35.1 million | $19.1 million | $100.6 million | $47.4 million |
| Net loss per share | $0.50 | $0.48 | $1.84 | $1.25 |
| Net cash used in operating activities | Not reported for quarter | Not reported for quarter | $89.2 million | $38.0 million |
- Q3 R&D growth reflected bezuclastinib trials and manufacturing, pipeline research, increased staffing, and laboratory and facility costs. Nine-month R&D expense increased $49.5 million year over year; G&A increased $4.7 million.
- At September 30, cash and cash equivalents were $140.6 million and marketable securities were $148.5 million, totaling $289.1 million. Current assets were $296.4 million versus current liabilities of $23.6 million. The company reported $41.6 million in total liabilities, including $20.1 million in operating lease liabilities; no debt balance is identified in the provided filing text.
- Nine-month investing cash outflow was $153.1 million, primarily purchases of marketable securities ($148.2 million) and property and equipment ($4.9 million). Financing provided $163.2 million, principally net proceeds of $161.9 million from the June public offering. Cash, cash equivalents and restricted cash declined $79.1 million to $141.8 million; this excludes marketable securities.
- No operating margin is meaningful given the absence of product revenue and ongoing development-stage losses. Accumulated deficit was $371.6 million.
Material changes and business developments
- In June 2022, Cogent completed an offering of common shares and pre-funded warrants, raising approximately $161.9 million net. It issued 17.9 million common shares and warrants for up to 3.0 million shares; 2.4 million warrants had been exercised by September 30. The filing reports 69.9 million common shares outstanding at quarter-end.
- Operating cash use rose to $89.2 million from $38.0 million in the comparable nine-month period, reflecting higher development spending and larger operating losses. Q3 net loss increased to $35.1 million from $19.1 million.
- The company recorded a $0.4 million impairment charge related to its former Cambridge office space after moving its headquarters to Waltham. It also commenced a 12-year Boulder research-facility lease, contributing to higher right-of-use assets and lease liabilities.
Outlook, commentary and risks
- Management stated that $289.1 million of cash, cash equivalents and marketable securities was expected to fund operating expenses and capital expenditure requirements into 2025, based on current plans and assumptions. The filing also notes the estimate could prove wrong and that additional funding will be required to complete planned research and development.
- PEAK, a Phase 3 GIST trial of bezuclastinib plus sunitinib versus sunitinib alone, had begun its randomized portion using a new 600 mg formulation. The company expected initial PEAK lead-in efficacy data in the first half of 2023. It planned to present updated APEX data in December 2022 and expected initial SUMMIT data in the second half of 2023.
- In preliminary APEX data with a May 24, 2022 cutoff, 11 of 11 treated patients had at least a 50% reduction in serum tryptase; 8 of 8 assessed patients had at least a 50% reduction in bone marrow mast cells. Management emphasized the early nature of these results and the small patient sample. SUMMIT enrollment and site start-up had been slower than initially forecast.
- Cogent reported it remained on track to file an IND in 2023 for its FGFR2 program. Its ErbB2 program remained preclinical. These are development plans, not guarantees of timing or outcomes.
- Key risks include clinical-trial failure or delay, limited early-trial sample sizes, regulatory uncertainty, competition, reliance on third-party manufacturers and sole-source bezuclastinib API and drug-product suppliers, and the need for additional capital. Financing could dilute shareholders or require the company to relinquish rights. COVID-19 and other disruptions could affect trials, supply and operations.
- No material legal proceedings were reported. The filing describes a $3.1 million contingent value right liability, with any remaining settlement payable in cash. No formal revenue or earnings guidance was provided.
Important facts for investors to verify
- Progress, enrollment and data quality in PEAK, APEX and SUMMIT, including how later or complete results compare with preliminary findings and management’s stated timelines.
- Whether the new bezuclastinib formulation performs as intended in trials and whether the company can address single-source supply dependencies.
- Actual cash burn, investment balances and runway relative to management’s “into 2025” estimate, including the impact of trial expansion and Boulder facility spending.
- Potential dilution from outstanding preferred shares convertible into approximately 20.3 million common shares, remaining pre-funded warrants, equity plans and future financing.
- Progress toward the planned 2023 FGFR2 IND and the scale and funding needs of the broader pipeline.